更多注册会员是一个结果。决策在于选择哪条路径可以重复操作，而不会让风险收入分成超过归因结果带来的回报。 数字健康公司面临特定困境——结果风险承担速度快于公司判断自身能否承受的速度，12个月测量窗口对上11个月销售周期。在定价完成前，风险收入分成会因无法归因的原因持续变动，渠道CAC的讨论也将停留在主观层面。
更多注册会员是一个结果。决策在于选择哪条路径可以重复操作，而不会让风险收入分成超过归因结果带来的回报。 数字健康公司面临特定困境——结果风险承担速度快于公司判断自身能否承受的速度，12个月测量窗口对上11个月销售周期。在定价完成前，风险收入分成会因无法归因的原因持续变动，渠道CAC的讨论也将停留在主观层面。
几乎每家数字健康公司都能列出几种注册会员的方式，但很少能说出哪一种在测量窗口结束后还能回本。这才是真实约束：不是缺少战术，而是缺乏证据判断在收入与参与率和客户流失挂钩时该放大哪种战术。
有效框架是路径经济学。对每条可行路径，需计算通过风险收入分成或PMPM获取一名注册会员的成本、归因结果覆盖该成本所需时间，以及路径能否在规模扩大时不推高成本。
多数路径过不了第三项测试。早期注册靠CEO或CFO与支付方、提供商的关系，一旦注意力转向下一个合同，路径就停止产出。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 注册会员增长跟随CEO或CFO日程，而非CRM中可见的可重复流程。
✓ 每名注册会员成本仅以汇总PMPM数字呈现，无按路径或风险收入分成回收部分的拆分。
✓ 多个渠道同时运行试点，参与率和客户流失保持不变，因为没有一条渠道达到测量归因结果所需的量级。
通常会让情况更糟的做法。 同时以低于规模的预算运行多条获客路径，导致每条路径在参与率和风险收入分成上都得出无结论的结果，而总支出增速快于任何单条路径的测试速度。
It is for you if you run or finance a digital health company and growth depends on one person's relationships. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Pricing Strategy · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Go-to-Market & Commercial Strategy, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
买家已经在的、且能在你能融资的周期内回本的渠道。这是业务具体问题，通用答案价值很低。
先运行一个有效的，再加第二个。以四分之一必要预算运行四个渠道，通常得到四个无结论结果和“什么都不行”的结论。
你的销售周期加一个回本周期，加上足够区分结果与噪声的量级。提前设定这个数字，能避免决策被最会说服的人主导。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית